Elisha Finney Sells 378 Shares of ICU Medical (NASDAQ:ICUI) Stock

Key Points

• Director Elisha Finney sold 378 ICU Medical shares for approximately $68,977 at an average price of $182.48, reducing her direct ownership by 7.2% to 4,871 shares.
• ICU Medical reported quarterly EPS of $2.37, beating estimates by $0.46, while revenue reached $547.88 million, up 0.5% year over year. The company issued fiscal 2026 EPS guidance of $8.60–$9.00.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $192.80; shares recently traded near $182, close to the target.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) Director Elisha Finney sold 378 shares of the company's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the completion of the transaction, the director directly owned 4,871 shares in the company, valued at approximately $888,860.08. This represents a 7.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

ICU Medical Stock Performance

Shares of ICUI traded down $0.34 during midday trading on Tuesday, reaching $182.08. 250,319 shares of the stock were exchanged, compared to its average volume of 297,071. ICU Medical, Inc. has a twelve month low of $107.50 and a twelve month high of $192.85. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The company has a market cap of $4.55 billion, a P/E ratio of 154.31, a PEG ratio of 2.58 and a beta of 0.74. The stock's 50 day simple moving average is $152.66 and its 200 day simple moving average is $141.12.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts' consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same period last year, the firm earned $2.10 earnings per share. ICU Medical's revenue for the quarter was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, sell-side analysts expect that ICU Medical, Inc. will post 6.51 earnings per share for the current year.

Institutional Trading of ICU Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Allworth Financial LP bought a new position in shares of ICU Medical in the 2nd quarter valued at $26,000. Hilton Head Capital Partners LLC acquired a new position in ICU Medical in the 4th quarter worth about $32,000. Covestor Ltd raised its position in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 126 shares during the last quarter. Strs Ohio raised its position in ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier's stock valued at $114,000 after purchasing an additional 300 shares during the last quarter. Finally, Rockefeller Capital Management L.P. boosted its stake in shares of ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier's stock valued at $117,000 after purchasing an additional 146 shares in the last quarter. Institutional investors own 96.10% of the company's stock.

Wall Street Analyst Weigh In

ICUI has been the subject of several analyst reports. Piper Sandler lifted their price objective on ICU Medical from $163.00 to $195.00 and gave the company an "overweight" rating in a report on Friday. Zacks Research cut ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Sanford C. Bernstein downgraded ICU Medical to a "market perform" rating in a research note on Monday, June 15th. BTIG Research increased their price objective on shares of ICU Medical from $170.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday. Finally, KeyCorp raised their target price on shares of ICU Medical from $164.00 to $182.00 and gave the company an "overweight" rating in a report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, ICU Medical presently has an average rating of "Moderate Buy" and a consensus price target of $192.80.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source